Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com
Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com
Equities research analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Rating) in a report issued on Thursday. The firm set a "sell" rating on the stock.
Ayala Pharmaceuticals Stock Performance
Shares of ADXS traded up $0.14 on Thursday, reaching $1.50. The stock had a trading volume of 3,325 shares, compared to its average volume of 7,793. Ayala Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $10.71.
Get Ayala Pharmaceuticals alerts:About Ayala Pharmaceuticals
(Get Rating)
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
See Also
- Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (ADXS)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Carvana May Be Able To Reach Profitability This Year
- Low Volume Bunge Plunge Presents an Opportunity
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Equities research analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Rating) in a report issued on Thursday. The firm set a "sell" rating on the stock.
股票研究分析師承擔股票報導 阿亞拉製藥 (納斯達克:ADXS — 獲得評級) 在星期四發布的報告中。該公司對股票設定了「賣出」評級。
Ayala Pharmaceuticals Stock Performance
阿亞拉製藥股票性能
Shares of ADXS traded up $0.14 on Thursday, reaching $1.50. The stock had a trading volume of 3,325 shares, compared to its average volume of 7,793. Ayala Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $10.71.
ADXS 的股票在周四上漲了 0.14 美元,達到 1.50 美元。該股的交易量為 3,325 股,相比其平均交易量為 7,793。阿亞拉製藥有 12 個月低點 $1.00 和 12 個月高點 $10.71.
About Ayala Pharmaceuticals
關於阿亞拉製藥
(Get Rating)
(取得評分)
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Advaxis, Inc 是一家生物技術公司,致力於癌症免疫療法的發現、開發和商業化。它管理的平台技術,利用活衰減李斯特菌單核基因生物工程分泌抗原或輔助融合蛋白.該公司在臨床和臨床前發展的不同階段擁有四個專營權,分別是 HPV 相關癌症、前列腺癌、新抗原治療和熱點突變治療。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (ADXS)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Carvana May Be Able To Reach Profitability This Year
- Low Volume Bunge Plunge Presents an Opportunity
- 獲取有關阿亞拉製藥(ADXS)的研究報告的免費副本
- KB 首頁強勁業績提升價格
- 耐嚼的股票正在建立長期盈利增長
- 為什麼華爾街喜歡這 3 竹篙股票
- 卡瓦納今年可能能夠達到盈利能力
- 低容量邦吉暴跌提出了機會
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收阿亞拉製藥日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收阿亞拉製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧